Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by TransCode Therapeutics, Inc.
< Previous
1
2
Next >
TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors
April 15, 2024
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RNAZ
TransCode Therapeutics Reports 2023 Results; Provides Business Update
April 03, 2024
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RNAZ
TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer
March 28, 2024
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RNAZ
TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment
March 11, 2024
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RNAZ
TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress
March 06, 2024
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RNAZ
TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist Immunotherapeutic
February 20, 2024
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RNAZ
Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders’ Equity Requirement and Continued Listing on The Nasdaq Stock Market
January 31, 2024
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RNAZ
TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer
January 29, 2024
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RNAZ
TransCode Therapeutics Announces Closing of $7.25 Million Public Offering
January 22, 2024
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RNAZ
TransCode Therapeutics Announces Pricing of $7.25 Million Public Offering
January 18, 2024
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RNAZ
TransCode Therapeutics Reports Further Restructuring to Reduce Expenses and Increased Focus on Planned Phase 1 Clinical Trial, Retirement of CEO
January 12, 2024
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RNAZ
TransCode Therapeutics Announces 1-for-40 Reverse Stock Split
January 11, 2024
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RNAZ
TransCode Therapeutics Publishes Open Letter Outlining Company’s Progress and Objectives
January 04, 2024
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RNAZ
TransCode Therapeutics Reports Positive Pre-Clinical Results in Metastatic Pancreatic Cancer with its Lead Candidate, TTX-MC138
December 12, 2023
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RNAZ
TransCode Therapeutics To Present Phase 0 Data at 2023 San Antonio Breast Cancer Symposium
December 05, 2023
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RNAZ
TransCode Therapeutics Announces Closing of $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules
December 04, 2023
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RNAZ
TransCode Therapeutics Announces $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules
November 30, 2023
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RNAZ
TransCode Therapeutics Reports Third Quarter 2023 Results; Provides Business Update
November 14, 2023
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RNAZ
TransCode Therapeutics Withdraws Public Offering
October 30, 2023
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RNAZ
Nasdaq Panel Grants TransCode Therapeutics Extension for Continued Listing on The Nasdaq Stock Market Subject to Conditions
October 27, 2023
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RNAZ
TransCode Therapeutics Announces Public Offering of Common Stock
October 26, 2023
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RNAZ
TransCode Therapeutics Announces Prolonged Survival in Murine Models with Glioblastoma Treated with Its Lead Candidate, TTX-MC138
October 26, 2023
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RNAZ
TransCode Therapeutics Announces Preliminary Clinical Results in First Patient in Phase 0 Clinical Study with Lead Therapeutic Candidate, TTX-MC138
October 24, 2023
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RNAZ
TransCode Therapeutics Reports Successful Treatment of Preclinical Melanoma Tumors with its Immunotherapy Candidate, TTX-RIGA
October 16, 2023
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RNAZ
TransCode Therapeutics Announces Closing of $8.5 Million Public Offering
September 28, 2023
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RNAZ
TransCode Therapeutics Announces Pricing of $8 Million Public Offering
September 25, 2023
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RNAZ
TransCode Therapeutics Announces Positive Pre-Clinical Glioblastoma Results with Lead Therapeutic Candidate, TTX-MC138
September 25, 2023
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RNAZ
TransCode Therapeutics Announces First Subject Dosed with Radiolabeled TTX-MC138 in First-In-Human Clinical Trial
August 23, 2023
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RNAZ
TransCode Therapeutics Reports Second Quarter 2023 Results; Provides Business Update
August 14, 2023
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RNAZ
TransCode Therapeutics Announces Positive Results in Non-human Primates with its Lead Therapeutic Candidate, TTX-MC138
July 31, 2023
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RNAZ
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.